Dave is a co-founder of Iksuda Therapeutics and has >20 years of experience in Biotech & Pharma, primarily in the development & commercialization of biotherapeutics.

Previously, Dave established Eden Biodesign - a CDMO service to biotech clients across the world – which was acquired by Watson Pharmaceuticals and, ultimately, Allergan. Whilst at Allergan, Dave led rFSH to its Phase I clinical trial.